Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells

International Journal of Molecular Medicine

Volumn 36, Issue 5, 2015, Pages 1223-1232

  Lu, Yao ^a   Li, Su ^a   Wu, Hengfang ^a   Bian, Zhiping ^a   Xu, Jindan ^a   Gu, Chunrong ^a   Chen, Xiangjian ^a   Yang, Di ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Astragaloside IV; Mitochondrial dysfunction; ROS; Smooth muscle cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; ASTRAGALOSIDE IV; DYNAMIN 1 LIKE PROTEIN 1; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; OXYGEN; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; XANTHINE OXIDASE; ANTIOXIDANT; ASTRAGALOSIDE A; PPARGC1A PROTEIN, RAT; SAPONIN; TRANSCRIPTION FACTOR; TRITERPENE;

ANIMAL CELL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; IN VITRO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL DISEASES; MITOCHONDRION; OXIDATION REDUCTION REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DNA, MITOCHONDRIAL; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; OXIDATION-REDUCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SAPONINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRITERPENES;

EID: 84945399884     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2345     Document Type: Article

References (48)

1. Yu E, Calvert PA, Mercer JR, Harrison J, Baker L, Figg NL, Kumar S, Wang JC, Hurst LA, Obaid DR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells, and monocytes, and correlates with higher-risk plaques in humans. Circulation. 128: 702-712, 2013
2. Mercer JR. Mitochondrial bioenergetics, and therapeutic intervention in cardiovascular disease. Pharmacol Ther. 141: 13-20, 2014
3. Dikalov SI, and Nazarewicz RR. Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms, and relevance for cardiovascular disease. Antioxid Redox Signal. 19: 1085-1094, 2013
4. Queliconi BB, Wojtovich AP, Nadtochiy SM, Kowaltowski AJ, and Brookes PS. Redox regulation of the mitochondrial K(ATP) channel in cardioprotection. Biochim Biophys Acta. 1813: 1309-1315, 2011
5. Dikalov S. Cross talk between mitochondria, and NADPH oxidases. Free Radic Biol Med. 51: 1289-1301, 2011
6. Doughan AK, Harrison DG, and Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage, and vascular endothelial dysfunction. Circ Res. 102: 488-496, 2008
7. Wang H, Zhang Y, Xia T, Wei W, Chen F, Guo X, and Li X. Synergistic promotion of blood vessel regeneration by astragaloside IV, and ferulic acid from electrospun fibrous mats. Mol Pharm. 10: 2394-2403, 2013
8. Ko JK, Lam FY, and Cheung AP. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation, and inhibition of adhesion molecule synthesis. World J Gastroenterol. 11: 5787-5794, 2005
9. Yang J, Wang HX, Zhang YJ, Yang YH, Lu ML, Zhang J, Li ST, Zhang SP, and Li G. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-?B signaling pathway in isoproterenol-induced myocardial hypertrophy. J Ethnopharmacol. 150: 1062-1070, 2013
10. Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, Liu X, and Wang N. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-?B mediated inflammatory genes expression. Cytokine. 61: 970-977, 2013
11. Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, et al. Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-Activated protein kinases, and antiapoptosis in vivo, and in vitro. J Pharmacol Exp Ther. 350: 552-562, 2014
12. Wu X, Cao Y, Nie J, Liu H, Lu S, Hu X, Zhu J, Zhao X, Chen J, Chen X, et al. Genetic, and pharmacological inhibition of Rheb1 mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol. 182: 2005-2014, 2013
13. Zhang WD, Zhang C, Wang XH, Gao PJ, Zhu DL, Chen H, Liu RH, and Li HL. Astragaloside IV dilates aortic vessels from normal, and spontaneously hypertensive rats through endothelium-dependent, and endothelium-independent ways. Planta Med. 72: 621-626, 2006
14. Yin Y, Qi F, Song Z, Zhang B, and Teng J. Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats. Biosci Trends. 8: 217-226, 2014
15. Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu W, and Tang L. Effects of Astragaloside IV on heart failure in rats. Chin Med. 4: 6, 2009
16. Xu XL, Ji H, Gu SY, Shao Q, Huang QJ, and Cheng YP. Modification of alterations in cardiac function, and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo. Eur J Pharmacol. 568: 203-212, 2007
17. Qiu LH, Xie XJ, and Zhang BQ. Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biol Pharm Bull. 33: 641-646, 2010
18. Sun L, Li W, Li W, Xiong L, Li G, and Ma R. Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF ?B pathway under high glucose conditions. Int J Mol Med. 34: 167-176, 2014
19. Sun Q, Jia N, Wang W, Jin H, Xu J, and Hu H. Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening. PLoS One. 9: e98866, 2014
20. Hu JY, Han J, Chu ZG, Song HP, Zhang DX, Zhang Q, and Huang YS. Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels. Clin Exp Pharmacol Physiol. 36: 351-357, 2009
21. Tu L, Pan CS, Wei XH, Yan L, Liu YY, Fan JY, Mu HN, Li Q, Li L, Zhang Y, et al. Astragaloside IV protects heart from ischemia, and reperfusion injury via energy regulation mechanisms. Microcirculation. 20: 736-747, 2013
22. Shen Y, Tian Y, Yang J, Shi X, Ouyang L, Gao J, and Lu J. Dual effects of carnosine on energy metabolism of cultured cortical astrocytes under normal, and ischemic conditions. Regul Pept. 192-193: 45-52, 2014
23. Mukhopadhyay P, Rajesh M, Haskó G, Hawkins BJ, Madesh M, and Pacher P. Simultaneous detection of apoptosis, and mitochondrial superoxide production in live cells by flow cytometry, and confocal microscopy. Nat Protoc. 2: 2295-2301, 2007
24. Laurindo FR, de Souza HP, Pedro MA, and Janiszewski M. Redox aspects of vascular response to injury. Methods Enzymol. 352: 432-454, 2002
25. Herst PM, and Berridge MV. Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim Biophys Acta. 1767: 170-177, 2007
26. Xie H, Lev D, Gong Y, Wang S, Pollock RE, Wu X, and Gu J. Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. Carcinogenesis. 34: 1039-1043, 2013
27. Elahi MM, Kong YX, and Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev. 2: 259-269, 2009
28. Wei Y, Clark SE, Thyfault JP, Uptergrove GM, Li W, Whaley Connell AT, Ferrario CM, Sowers JR, and Ibdah JA. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol. 174: 1329-1337, 2009
29. Prathapan A, Vineetha VP, and Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One. 9: e96220, 2014
30. Schulz E, Wenzel P, Munzel T, and Daiber A. Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal. 20: 308-324, 2014
31. Lijnen PJ, van Pelt JF, and Fagard RH. Downregulation of manganese superoxide dismutase by angiotensin II in cardiac fibroblasts of rats: Association with oxidative stress in myocardium. Am J Hypertens. 23: 1128-1135, 2010
32. Touyz RM. Reactive oxygen species, and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res. 37: 1263-1273, 2004
33. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, and Abe Y. Mitochondria-derived reactive oxygen species, and vascular MAP kinases: comparison of angiotensin II, and diazoxide. Hypertension. 45: 438-444, 2005
34. Zablocki D, and Sadoshima J. Angiotensin II, and oxidative stress in the failing heart. Antioxid Redox Signal19: 1095-1109, 2013
35. Bedard K, and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology, and pathophysiology. Physiol Rev. 87: 245-313, 2007
36. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N, and Takeshita A. Oxidative stress mediates tumor necrosis factor-Alpha-induced mitochondrial DNA damage, and dysfunction in cardiac myocytes. Circulation. 107: 1418-1423, 2003
37. Li H, Horke S, and Förstermann U. Oxidative stress in vascular disease, and its pharmacological prevention. Trends Pharmacol Sci. 34: 313-319, 2013
38. Qi W, Niu J, Qin Q, Qiao Z, and Gu Y. Astragaloside IV attenuates glycated albumin-induced epithelial-To-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones. 19: 105-114, 2014
39. Wang YY, Peng Y, Zhang Q, Wu YN, Song JQ, and Liu YX. Effect of ERK1/2 signaling pathway on astragaloside IV protects H9c2 cells against H2O2-induced oxidative injury. Zhongguo Ying Yong Sheng Li Xue Za Zh27: 363-367, 2011 (In Chinese)
40. Mammucari C, and Rizzuto R. Signaling pathways in mitochondrial dysfunction, and aging. Mech Ageing Dev. 131: 536-543, 2010
41. Lee J, Giordano S, and Zhang J. Autophagy, mitochondria, and oxidative stress: cross-Talk, and redox signalling. Biochem J. 441: 523-540, 2012
42. Narendra DP, and Youle RJ. Targeting mitochondrial dysfunction: role for PINK1, and Parkin in mitochondrial quality control. Antioxid Redox Signal. 14: 1929-1938, 2011
43. Kageyama Y, Hoshijima M, Seo K, Bedja D, Sysa-Shah P, Andrabi SA, Chen W, Höke A, Dawson VL, Dawson TM, et al. Parkin-independent mitophagy requires Drp1, and maintains the integrity of mammalian heart, and brain. EMBO J. 33: 2798-2813, 2014
44. Deng H, Dodson MW, Huang H, and Guo M. The Parkinson's disease genes pink1, and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA. 105: 14503-14508, 2008
45. Wang Y, Nartiss Y, Steipe B, McQuibban GA, and Kim PK. ROS-induced mitochondrial depolarization initiates PARK2/PARKIN-dependent mitochondrial degradation by autophagy. Autophagy. 8: 1462-1476, 2012
46. Scarpulla RC, Vega RB, and Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab. 23: 459-466, 2012
47. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, and Spiegelman BM. Mechanisms controlling mitochondrial biogenesis, and respiration through the thermogenic coactivator PGC-1. Cell. 98: 115-124, 1999
48. Biala A, Tauriainen E, Siltanen A, Shi J, Merasto S, Louhelainen M, Martonen E, Finckenberg P, Muller DN, and Mervaala E. Resveratrol induces mitochondrial biogenesis, and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin, and angiotensinogen genes. Blood Press. 19: 196-205, 2010